Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Narisa Tantai"'
Autor:
Pongtawat Lertwilaiwittaya, Narisa Tantai, Satanun Maneeon, Sophittha Kongbunrak, Nongyao Nonpanya, Anna C. E. Hurst, Varalak Srinonprasert, Manop Pithukpakorn
Publikováno v:
Frontiers in Public Health, Vol 11 (2023)
BackgroundScreening for germline pathogenic BRCA1 or BRCA2 variants (gBRCA) in high-risk breast cancer patients is known to be cost-effective in high-income countries. Nationwide adoption of genetics testing in high-risk breast cancer population rema
Externí odkaz:
https://doaj.org/article/9c42fe475ab340979c9f9ea2b5f9d63c
Autor:
Pongtawat Lertwilaiwittaya, Manop Pithukpakorn, Varalak Srinonprasert, Narisa Tantai, Satanun Maneeon, Ryan Kraemer, Anna Hurst
Publikováno v:
Genetics in Medicine Open, Vol 1, Iss 1, Pp 100405- (2023)
Externí odkaz:
https://doaj.org/article/8e02b434cee3404db2ec2881ed835fca
Autor:
Chayanan Thanakiattiwibun, Arunotai Siriussawakul, Tithita Virotjarumart, Satanun Maneeon, Narisa Tantai, Varalak Srinonprasert, Onuma Chaiwat, Patcharee Sriswasdi
Publikováno v:
Medicine. 102:e33389
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::559eda00779264b4cdbfbd7e10c10431
https://doi.org/10.1097/md.0000000000033389
https://doi.org/10.1097/md.0000000000033389
Autor:
Narisa Tantai1 narisatan@gmail.com, Usa Chaikledkaew2,3 usa.chi@mahidol.ac.th, Tawesak Tanwandee4 tawesak@gmail.com, Pitsaphun Werayingyong3 pitsaphun.w@hitap.net, Yot Teerawattananon3 yot.t@hitap.net
Publikováno v:
BMC Health Services Research. 2014, Vol. 14 Issue 1, p1-24. 24p. 1 Diagram, 3 Charts, 2 Graphs.
Autor:
Thirawud Khuhaprema, Wirote Lausoontornsiri, Yot Teerawattananon, Narisa Tantai, Somjin Chindavijak, Panattharin Lerdkiattikorn, Usa Chaikledkaew
Publikováno v:
Expert Review of Pharmacoeconomics & Outcomes Research. 15:687-700
In Thailand, there has been no economic evaluation study of adjuvant chemotherapy for stage III colon cancer patients after resection.This study aims to evaluate the cost-utility of all chemotherapy regimens currently used in Thailand compared with t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e340345867c88cf1d3862640df7d0aa5
https://doi.org/10.1586/14737167.2015.972379
https://doi.org/10.1586/14737167.2015.972379
Autor:
Usa Chaikledkaew, Yot Teerawattananon, Pitsaphun Werayingyong, Tawesak Tanwandee, Narisa Tantai
Publikováno v:
BMC Health Services Research
Background Only lamivudine has been included for patients with chronic hepatitis B (CHB) in the National List of Essential Drugs (NLED), a pharmaceutical reimbursement list in Thailand. There have also been no economic evaluation studies of CHB drug
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fa20b5885846df6ddcd9af2da3510b5
https://doi.org/10.1186/1472-6963-14-170
https://doi.org/10.1186/1472-6963-14-170